-
1Academic Journal
Συγγραφείς: B. Ya. Alekseev, V. M. Perepukhov, K. M. Nyushko, M. G. Poltavskaya, Б. Я. Алексеев, В. М. Перепухов, К. М. Нюшко, М. Г. Полтавская
Πηγή: Cancer Urology; Том 20, № 3 (2024); 80-93 ; Онкоурология; Том 20, № 3 (2024); 80-93 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: лейпрорелин, overall survival, androgen deprivation therapy, cardiovascular complication, luteinizing hormone-releasing hormone agonist, luteinizing hormone-releasing hormone antagonist, leuprorelin, общая выживаемость, андрогендепривационная терапия, сердечно-сосудистое осложнение, агонист лютеинизирующего гормона рилизинг-гормона, антагонист лютеинизирующего гормона рилизинг-гормона
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1876/1559; Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI:10.3322/caac.21660; Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 262 с.; Рак предстательной железы. Клинические рекомендации. Минздрав РФ, 2021.; Jonušas J., Drevinskaitė М., Patašius А. et al. Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study. Aging Male 2022;25(1):173–9. DOI:10.1080/13685538.2022.2091130; Keating N.L., O’Malley A.J., Freedland S.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102(1):39–46. DOI:10.1093/jnci/djp404; Saigal C.S., Gore J.L., Krupski T.L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110(7):1493–500. DOI:10.1002/cncr.22933; Van Hemelrijck M., Garmo H., Holmberg L. et al. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol 2012;61(4):690–700. DOI:10.1016/j.eururo.2011.09.010; GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1736–88. DOI:10.1016/S0140-6736(18)32203-7; Mensah G.A., Fuster V., Murray C.J.L. et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol 2023;82(25):2350–473. DOI:10.1016/j.jacc.2023.11.007; Armenian S.H., Xu L., Ky B. et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 2016;34(10):1122–30. DOI:10.1200/JCO.2015.64.0409; Mulrooney D.A., Yeazel M.W., Kawashima T. et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606. DOI:10.1136/bmj.b4606; Haugnes H.S., Wethal T., Aass N. et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28(30):4649–57. DOI:10.1200/JCO.2010.29.9362; Lenihan D.J., Cardinale D.M. Late cardiac effects of cancer treatment. J Clin Oncol 2012;30(30):3657–64. DOI:10.1200/JCO.2012.45.2938; Coleman M.P., Gatta G., Verdecchia A. et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003;14:v128–49. DOI:10.1093/annonc/mdg756; Sturgeon K.M., Deng L., Bluethmann S.M. et al. A populationbased study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40(48):3889–97. DOI:10.1093/eurheartj/ehz766; Leong D.P., Fradet V., Shayegan B. et al. Cardio-vascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol 2020;203(6):1109–16. DOI:10.1097/JU.0000000000000714; Smith M.R., Klotz L., van der Meulen E. et al. Gonadotropinreleasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186(5):1835–42. DOI:10.1016/j.juro.2011.07.035; Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. Cancer J Clin 2022;72(1):7–33. DOI:10.3322/caac.21708; Klimis H., Pinthus J.H., Aghel N. et al. The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis. JACC CardioOncol 2023;5(1):70–81. DOI:10.1016/j.jaccao.2022.09.008; Goodale T., Sadhu A., Petak S., Robbins R. Testosterone and the heart. Methodist Debakey Cardiovasc J 2017;13(2):68–72. DOI:10.14797/mdcj-13-2-68; Brouillette J., Rivard K., Lizotte E., Fiset C. Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc Res 2005;65(1):148–57. DOI:10.1016/j.cardiores.2004.09.012; Tsang S., Wu S., Liu J., Wong T.M. Testosterone protects rat hearts against ischaemic insults by enhancing the effects of α1-adrenoceptor stimulation. Br J Pharmacol 2008;153(4): 693–709. DOI:10.1038/sj.bjp.0707624; Campelo A.E., Cutini P.H., Massheimer V.L. Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway. J Endocrinol 2012;213(1):77–87. DOI:10.1530/JOE-11-0441; Scragg J.L., Jones R.D., Channer K.S. et al. Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochem Biophys Res Commun 2004;318(2):503–6. DOI:10.1016/j.bbrc.2004.04.054; Tzortzis V., Samarinas M., Zachos I. et al. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones 2017;16(2):115–23. DOI:10.14310/horm.2002.1727; Panagiotis M.I., Papatsoris A.G., Siasos G. et al. The effect of androgen deprivation therapy in arterial stiffness of the aorta and the endothelial function of peripheral arteries. Urol Nephrol Open Access J 2014;1(2):42–5.; Hopmans S.N., Duivenvoorden W.C., Werstuck G.H. et al. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol 2014;32(8):1126–34. DOI:10.1016/j.urolonc.2014.06.018; Poljak Z., Hulin I., Maruscakova L., Mladosievicova B. Are GnRH and FSH potentially damaging factors in the cardiovascular system? Pharmazie 2018;73(4):187–90. DOI:10.1691/ph.2018.7992; Crawford E.D., Schally A.V., Pinthus J.H. et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol 2017;35(5):183–91. DOI:10.1016/j.urolonc.2017.01.025; Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 2008;29(5):534–9. DOI:10.2164/jandrol.108.005454; Wang T., Li M., Zeng T. et al. Association between insulin resistance and cardiovascular disease risk varies according to glucose tolerance status: a nationwide prospective cohort study. Diabetes Care 2022;45(8):1863–72. DOI:10.2337/dc22-0202; Herink M., Ito M.K. Medication induced changes in lipid and lipoproteins. Eds.: K.R. Feingold, B. Anawalt, M.R. Blackman et al. Endotext. MDText.com, Inc, 2000.; Pol T., Held C., Westerbergh J. et al. Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. J Am Heart Assoc 2018;7(3):e007444. DOI:10.1161/JAHA.117.007444; Katsoulis M., Stavola B.D., Diaz-Ordaz K. et al. Weight change and the onset of cardiovascular diseases: emulating trials using electronic health records. Epidemiology 2021;32(5):744–55. DOI:10.1097/EDE.0000000000001393; Seible D.M., Gu X., Hyatt A., Beard C. Identifying men at greatest risk of weight gain from androgen deprivation therapy. J Clin Oncol 2014;32(4_suppl):80. DOI:10.1200/jco.2014.32.4_suppl.80; Nelson A.J., Lopes R.D., Hong H. et al. Cardiovascular effects of GnRH antagonists compared with agonists in prostate cancer: a systematic review. JACC CardioOncol 2023;5(5):613–24. DOI:10.1016/j.jaccao.2023.05.011; Cicione A., Nacchia A., Guercio A. et al. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. Prostate Cancer Prostatic Dis 2023;26(4):765–71. DOI:10.1038/s41391-022-00640-4; Lopes R.D., Higano C.S., Slovin S.F. et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 2021;144(16):1295–307. DOI:10.1161/CIRCULATIONAHA.121.056810; Kokorovic A., So A.I., Serag H. et al. UPDATE–Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Can Urol Assoc J 2022;16(8): E416–31. DOI:10.5489/cuaj.8054; Crawford E.D., Hafron J.M., Debruyne F. et al. Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a gonadotropin-releasing hormone antagonist. J Urol 2024;211(1):63–70. DOI:10.1097/JU.0000000000003721; Crawford E.D., Hafron J.M., Tagawa S.T. et al. Impact of late dosing on testosterone suppression with 2 different leuprolide acetate formulations: in situ gel and microsphere. An Analysis of United States Clinical Data. J Urol 2021;205(2):554–60. DOI:10.1097/JU.0000000000001392; Patel S., Zhu K., Dav C.V. et al. Comparative cardiovascular safety of gonadotropin-releasing hormone antagonists and agonists among patients diagnosed with prostate cancer: a systematic review and meta-analysis of real-world evidence studies. Eur Urol Oncol 2024;S2588-9311(24)00213-X. DOI:10.1016/j.euo.2024.09.004; Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997;28(1):43–70. DOI:10.1016/s0169-409x(97)00050-1; Fujino M., Fukuda T., Shinagawa S. et al. Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem Biophys Res Commun 1974;60(1): 406–13. DOI:10.1016/0006-291x(74)90219-8; Abouelfadel Z., Crawford E.D. Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther Clin Risk Manag 2008;4(2):513–26. DOI:10.2147/tcrm.s686; Özyi̇ği̇t G., Akyol F. Cost-effectiveness analysis of leuprorelin acetate atrigel in the treatment of prostate cancer. Turkish Journal of Oncology 2020;35(4):430–7. DOI:10.5505/tjo.2020.2449; The European Medicines. Available at: Agencyhttps://www.ema.europa.eu/en/medicines/human/referrals/leuprorelin-containing-depotmedicinal-products; Tombal B., Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl 2005; 4(8):30–6. DOI:10.1016/J.EURSUP.2005.08.004; Dadey E.J. The atrigel drug delivery system. Modified-release drug delivery technology. CRC Press, 2008. Pp. 211–218.; Kempe S., Mäder K. In situ forming implants – an attractive formulation principle for parenteral depot formulations. J Control Release 2012;161(2):668–79. DOI:10.1016/j.jconrel.2012.04.016; Shimoyama M., Murata Y., Sumi K. et al. Docetaxel induced cardiotoxicity. Heart 2001;86:219. DOI:10.1136/heart.86.2.219; Bendahou H., Ettagmouti Y., Abouriche A. et al. Cardiotoxicity due to docetaxel rare but it exists: about a case and literature review. J Case Rep Med Hist 2023;3(1). DOI:10.54289/JCRMH2300105; Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. DOI:10.1056/NEJMoa1207506; Beer T.M., Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33. DOI:10.1056/NEJMc1410239; Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. DOI:10.1056/NEJMoa1903835; Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465–74. DOI:10.1056/NEJMoa1800536; Salem J.E., Yang T., Moslehi J.J. et al. Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019;140(13): 1070–80. DOI:10.1161/CIRCULATIONAHA.119.040162; Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408–18. DOI:10.1056/NEJMoa1715546; Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13–24. DOI:10.1056/NEJMoa1903307; Fizazi K., Shore N., Tammela T.L. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235–46. DOI:10.1056/NEJMoa1815671; Smith M.R., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132–42. DOI:10.1056/NEJMoa2119115; O'Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17α-hydroxylase/C17, 20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317–25. DOI:10.1038/sj.bjc.6601879; Attard G., Reid A.H.M., Auchus R.J. et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97(2):507–16. DOI:10.1210/jc.2011-2189; De Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005. DOI:10.1056/NEJMoa1014618; Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138–48. DOI:10.1056/NEJMoa1209096; Fizazi K., Tran N.P., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352–60. DOI:10.1056/NEJMoa1704174; Zhu X., Wu S. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. Clin Hypertens 2019;25:1–9. DOI:10.1186/s40885-019-0110-3; Salem J.E., Alexandre J., Bachelot A., Funck-Brentano C. Influence of steroid hormones on ventricular repolarization. Pharmacol Ther 2016;167:38–47. DOI:10.1016/j.pharmthera.2016.07.005; Iacovelli R., Ciccarese C., Bria E. et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 2018;16(3):e645–53. DOI:10.1016/j.clgc.2017.12.007; Lu-Yao G., Nikita N., Keith S.W. et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol 2020;77(2):158–66. DOI:10.1016/j.eururo.2019.07.031; Verzoni E., Grassi P., Ratta R. et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Ther Adv Med Oncol 2016;8(5):323–30. DOI:10.1177/1758834016656493; Lyon A.R., López-Fernández T., Couch L.S. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022;23(10):e333–465. DOI:10.1093/eurheartj/ehac244; Бойцов С.А., Погосова Н.В., Аншелес А.А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал 2023;28(5):5452. DOI:10.15829/1560-4071-2023-5452; Виценя М.В., Агеев Ф.Т., Орлова Р.В. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли 2023;13(#3s2):86–111.; Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021;42(34):3227–37.; Okwuosa T.M., Morgans A., Rhee J.W. et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med 2021;14(3):e000082. DOI:10.1161/HCG.0000000000000082; Wilk M., Waśko-Grabowska A., Skoneczna I., Szmit S. Angiotensin system inhibitors may improve outcomes of patients with castrationresistant prostate cancer during abiraterone acetate treatment— a cardio-oncology study. Front Oncol 2021;11:664741. DOI:10.3389/fonc.2021.664741; Salem J.E., Waintraub X., Courtillot C. et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation 2018;138(1):110–3. DOI:10.1161/CIRCULATIONAHA.118.034282; Crawford E.D., Garnick M.B., Eckel R.H. et al. A proposal for the comprehensive care of men on androgen deprivation therapy: recommendations from the multidisciplinary Prostate Cancer 360 Working Group. Urol Pract 2024;11(1):18–29. DOI:10.1097/UPJ.0000000000000473; Goff Jr D.C., Lloyd-Jones D.M., Bennett G. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 suppl 2):S49–73. DOI:10.1161/01.cir.0000437741.48606.98; Jayalath V.H., Clark R., Lajkosz K. et al. Statin use and survival among men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis. JAMA Netw Open 2022;5(11):e2242676. DOI:10.1001/jamanetworkopen.2022.42676; Общая характеристика лекарственного препарата Эрлеада (01.09.2023). Доступно по: http://eec.eaeunion.org/; https://oncourology.abvpress.ru/oncur/article/view/1876
-
2Academic Journal
Συγγραφείς: P. G. Berezin, V. V. Milovanov, A. A. Ivannikov, N. A. Ognerubov, П. Г. Березин, В. В. Милованов, А. А. Иванников, Н. A. Огнерубов
Πηγή: Research and Practical Medicine Journal; Том 10, № 1 (2023); 78-89 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 78-89 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1
Θεματικοί όροι: факторы риска, results of the 1 st line therapy, androgen deprivation therapy, risk factors, результаты 1‑й линии лечения, андрогендепривационная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/810/541; https://www.rpmj.ru/rpmj/article/downloadSuppFile/810/648; https://www.rpmj.ru/rpmj/article/downloadSuppFile/810/649; Костин А. А., Кульченко Н. Г., Толкачев А. О. Прогнозирование развития рака предстательной железы. Мультидисциплинарный подход. Вестник медицинского института “РЕАВИЗ”: реабилитация, врач и здоровье. 2017;1(25):60–67.; Костин А. А., Кульченко Н. Г., Толкачев А. О. Рак предстательной железы. Принципы ранней диагностики. Вестник Российского университета дружбы народов. Серия: Медицина. 2016;4:68–76.; Состояние онкологической помощи населения России в 2019 году. Под ред. А. Д. Каприна, В. В. Старинского, А.О.Шахзадова. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2020, 236 с. Доступно по: https://glavonco.ru/cancer_register/Помощь%202019.pdf. Дата обращения: 17.02.2023.; Злокачественные новообразования в России в 2019 году. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой (заболеваемость и смертность). М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020, 252 с. Доступно по: https://glavonco.ru/cancer_register/Забол_2019_Электр.pdf. Дата обращения: 17.02.2023.; Рак предстательной железы. Клинические рекомендации. Одобрено на заседании научно‑практического совета Министерства здравоохранения Российской Федерации (протокол от 25.12.2020 № 17‑4/4884). Доступно по: https://oncology‑association.ru/wp‑content/uploads/2021/02/rpzh.pdf. Дата обращения: 17.02.2023.; Алексеев Б. Я., Нюшко К. М. Интермиттирующая гормональная терапия у больных раком предстательной железы. Онкоурология. 2009;5(4):7–12.; Павлов А. Ю., Гафанов Р. А., Цыбульский А. Д., Фастовец С. В., Кравцов И. Б. Современная стратегия лекарственной терапии метастатического и кастрационно‑резистентного рака предстательной железы. РМЖ. 2016;8:476–479.; Матвеев В. Б., Халмурзаев О. А., Евсюкова О. И. Международный опыт применения олапариба при метастатическом кастрационно‑резистентном раке предстательной железы. Обзор литературы. Онкоурология. 2020;16(4):197–206. https://doi.org/10.17650/1726‑9776‑2020‑16‑4‑197‑206; Kirby M, Hirst C, Crawford ED. Characterising the castration‑resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov;65(11):1180–1192. https://doi.org/10.1111/j.1742‑1241.2011.02799.x; Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration‑resistant prostate cancer. Cancer Res. 2008 Aug 1;68(15):6407–6415. https://doi.org/10.1158/0008‑5472.can‑07‑5997; Mitsitades N, Schultz N, Taylor BS, Hiernymus H, Satagopan H, Scardino JP, et al. Prostate cancer Genome Project Group. Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for nowel personalized therapies. J Clin Oncol. 2009;27 (Suppl.): 15s; abstr. 5002.; Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration‑resistant tumor growth. Cancer Res. 2008 Jun 1;68(11):4447–4454. https://doi.org/10.1158/0008‑5472.can‑08‑0249; Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen‑independent prostate cancer. Cancer Res. 2006 Mar 1;66(5):2815–2825. https://doi.org/10.1158/0008‑5472.can‑05‑4000; Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone‑refractory metastatic prostate cancer. J Clin Oncol. 2003 Apr 1;21(7):1232–1237. https://doi.org/10.1200/jco.2003.06.100. Erratum in: J Clin Oncol. 2004 Aug 15;22(16):3434; Guidelines on Prostate Cancer. European Association of Urology Guidelines on Prostate Cancer 2015. Доступно по: https://www.researchgate.net/publication/274064386_European_Association_of_Urology_Guidelines_on_Prostate_Cancer_2015. Дата обращения: 17.02.2023.; Гарин А. М. Доцетаксел (Таксотер) в практике лечения злокачественных опухолей. М.: Клевер Принт; 2003, c. 88‑94.; Kish JA, Bukkapatnam R, Palazzo F. The treatment challenge of hormone‑refractory prostate cancer. Cancer Control. 2001 Nov-Dec;8(6):487–495. https://doi.org/10.1177/107327480100800603; Методические рекомендации по применению критериев ответа солидных опухолей на химиотерапевтическое лечение (recist 1.1). М., 2018. Доступно по: https://tele‑med.ai/biblioteka‑dokumentov/primeneniye_kriteriyev_otveta_solidnykh_ opukholey_na_khimioterapevticheskoye_lecheniye_recist_11. Дата обращения: 17.02.2023.; Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al.; Southwest Oncology Group Trial 9346 (INT‑0162). Absolute prostate‑specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT‑0162). J Clin Oncol. 2006 Aug 20;24(24):3984–3990. https://doi.org/10.1200/jco.2006.06.4246; Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal Therapy in Metastatic Hormone‑Sensitive Prostate Cancer: Long‑Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10;36(11):1080–1087. https://doi.org/10.1200/jco.2017.75.3657; James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long‑term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163–1177. https://doi.org/10.1016/s0140‑6736(15)01037‑5; Graff JN, Baciarello G, Armstrong AJ, Higano CS, Iversen P, Flaig TW, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy‑naive metastatic castration‑resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016 Feb;27(2):286–294. https://doi.org/10.1093/annonc/mdv542; Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double‑blind, phase 2 study. Lancet Oncol. 2016 Feb;17(2):153–163. https://doi.org/10.1016/s1470‑2045(15)00518‑5; Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al.; COU‑AA‑302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy‑naive men with metastatic castration‑resistant prostate cancer (COU‑AA‑302): final overall survival analysis of a randomised, double‑blind, placebo‑controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152–160. https://doi.org/10.1016/s1470‑2045(14)71205‑7; Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium‑223 dichloride in patients with castration‑resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double‑blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014 Nov;15(12):1397–1406. https://doi.org/10.1016/s1470‑2045(14)70474‑7; Алексеев Б. Я., Нюшко К. М., Рева С. А. Носов А. К., Прохоров Д. Г., Андабеков Т. Т., и др. Спасительная лимфоденэктомия у больных с лимфогенным прогрессированием рака предстательной железы после проведенного радикального лечения: результаты многоцентрового исследования. Онкоурология. 2016;12(4):70‑80. https://doi.org/10.17650/1726‑9776‑2016‑12‑4‑70‑80; https://www.rpmj.ru/rpmj/article/view/810
-
3Academic Journal
Συγγραφείς: A. A. Gritskevich, Ya. D. Prokhorova, T. P. Baitman, E. Yu. Gritskevich, A. A. Kostin, А. А. Грицкевич, Я. Д. Прохорова, Т. П. Байтман, Е. Ю. Грицкевич, А. А. Костин
Πηγή: Research and Practical Medicine Journal; Том 9, № 2 (2022); 143-155 ; Research'n Practical Medicine Journal; Том 9, № 2 (2022); 143-155 ; 2410-1893 ; 10.17709/2410-1893-2022-9-2
Θεματικοί όροι: андрогендепривационная терапия, prostate cancer, androgens, testosterone, androgen deprivation therapy, рак предстательной железы, андрогены, тестостерон
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/813/491; https://www.rpmj.ru/rpmj/article/downloadSuppFile/813/651; https://www.rpmj.ru/rpmj/article/downloadSuppFile/813/652; Малинникова Е. Ю. Новая коронавирусная инфекция. Сегодняшний взгляд на пандемию XXI века. Инфекционные болезни: новости, мнения, обучение. 2020;9(2):18–32. https://doi.org/10.33029/2305‑3496‑2020‑9‑2‑18‑32; Seymen CM. The other side of COVID‑19 pandemic: Effects on male fertility. J Med Virol. 2021 Mar;93(3):1396–1402. https://doi.org/10.1002/jmv.26667; World Health Organization (WHO). WHO Coronavirus (COVID‑19) Dashboard [Internet]. WHO; 2021. Доступно по: https://covid19.who.int/, Дата обращения: 25.04.2022.; Беляев А. М., Носов А. К., Игнатова О. К., Байрамов Х. Н., Рябинин Р. И., Щекутеев Н. А., и др. Метаморфозы онкоурологии после первой волны пандемии COVID‑19. Экспериментальная и клиническая урология. 2020;(3):16–24. https://doi.org/10.29188/2222‑8543‑2020‑12‑3‑16‑24; Foresta C, Rocca MS, Di Nisio A. Gender susceptibility to COVID‑19: a review of the putative role of sex hormones and X chromosome. J Endocrinol Invest. 2021 May;44(5):951–956. https://doi.org/10.1007/s40618‑020‑01383‑6; Каприн А. Д., Гамеева Е. В., Поляков А. А., Корниецкая А. Л., Рубцова Н. А., Феденко А. А. Влияние пандемии COVID‑19 на онкологическую практику. Сибирский онкологический журнал. 2020;19(3):5–22. https://doi.org/10.21294/1814‑4861‑2020‑19‑3‑5‑22; Zhou P P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–273. https://doi.org/10.1038/s41586‑020‑2012‑7; Hoffmann M, Kleine‑Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS‑CoV‑2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271–280. https://doi.org/10.1016/j.cell.2020.02.052; Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS‑CoV‑2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020 May 18;39(10):e105114. https://doi.org/10.15252/embj.20105114; Rahman N, Basharat Z, Yousuf M, Castaldo G, Rastrelli L, Khan H. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS‑CoV‑2). Molecules. 2020 May 12;25(10):2271. https://doi.org/10.3390/molecules25102271; Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen‑deprivation therapies for prostate cancer and risk of infection by SARS‑CoV‑2: a population‑based study (N = 4532). Ann Oncol. 2020 Aug;31(8):1040–1045. https://doi.org/10.1016/j.annonc.2020.04.479; Pinato DJ, Zambelli A, Aguilar‑Company J, Bower M, Sng C, Salazar R, et al. Clinical portrait of the SARS‑CoV‑2 epidemic in European cancer patients. Cancer Discov. 2020 Jul 31;10(10):1465–1474. https://doi.org/10.1158/2159‑8290.CD‑20‑0773; Cattrini C, Bersanelli M, Latocca MM, Conte B, Vallome G, Boccardo F. Sex Hormones and Hormone Therapy during COVID‑19 Pandemic: Implications for Patients with Cancer. Cancers (Basel). 2020 Aug 18;12(8):2325. https://doi.org/10.3390/cancers12082325; Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID‑19 in the New York City Area. JAMA. 2020 May 26;323(20):2052–2059. https://doi.org/10.1001/jama.2020.6775; Onder G, Rezza G, Brusaferro S. Case‑Fatality Rate and Characteristics of Patients Dying in Relation to COVID‑19 in Italy. JAMA. 2020 May 12;323(18):1775–1776. https://doi.org/10.1001/jama.2020.4683; Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708–1720. https://doi.org/10.1056/NEJMoa2002032; Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS‑CoV‑2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574–1581. https://doi.org/10.1001/jama.2020.5394; Stall NM, Wu W, Lapointe‑Shaw L, Fisman DN, Giannakeas V, Hillmer MP, et al. Sex‑and Age‑Specific Differences in COVID‑19 Testing, Cases, and Outcomes: A Population‑Wide Study in Ontario, Canada. J Am Geriatr Soc. 2020 Oct;68(10):2188–2191. https://doi.org/10.1111/jgs.16761; Lochlainn MN, Lee KA, Sudre CH, Varsavsky T, Cardoso MJ, Menni C, et al. Key predictors of attending hospital with COVID19: An association study from the COVID Symptom Tracker App in 2,618,948 individuals. medRxiv. 2020 Jan 1;2020.04.25.20079251. https://doi.org/10.1101/2020.04.25.20079251; Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID‑19 outcomes. Nat Rev Immunol. 2020 Jul;20(7):442–447. https://doi.org/10.1038/s41577‑020‑0348‑8; Handelsman DJ, Hirschberg AL, Bermon S. Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance. Endocr Rev. 2018 Oct 1;39(5):803–829. https://doi.org/10.1210/er.2018‑00020; Grossmann M, Ng Tang Fui M, Cheung AS. Late‑onset hypogonadism: metabolic impact. Andrology. 2020 Nov;8(6):1519–1529. https://doi.org/10.1111/andr.12705; Assyov Y, Gateva A, Karamfilova V, Gatev T, Nedeva I, Velikova T, et al. Impact of testosterone treatment on circulating irisin in men with late‑onset hypogonadism and metabolic syndrome. Aging Male. 2020 Dec;23(5):1381–1387. https://doi.org/10.1080/13685538.2020.1770721; Schroeder M, Schaumburg B, Müller Z, Parplys A, Jarczak D, Nierhaus A, et al. Sex hormone and metabolic dysregulations are associated with critical illness in male Covid‑19 patients. medRxiv. 2020 Jan 1;2020.05.07.20073817. https://doi.org/10.1101/2020.05.07.20073817; Shen LW, Qian MQ, Yu K, Narva S, Yu F, Wu YL, et al. Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G‑quadruplex and hence down‑regulating TMPRSS2 expression. Sci Rep. 2020 May 6;10(1):7635. https://doi.org/10.1038/s41598‑020‑64368‑8; Piva F, Sabanovic B, Cecati M, Giulietti M. Expression and co‑expression analyses of TMPRSS2, a key element in COVID‑19. Eur J Clin Microbiol Infect Dis. 2021 Feb;40(2):451–455. https://doi.org/10.1007/s10096‑020‑04089‑y; Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS‑CoV‑2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‑19 risk factors. Allergy. 2020 Nov;75(11):2829–2845. https://doi.org/10.1111/all.14429; Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020 Jul;146(1):80–88.e8. https://doi.org/10.1016/j.jaci.2020.05.004; Tang L, Zhu Q, Wang Z, Shanahan CM, Bensen JT, Fontham ETH, et al. Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):990–999. https://doi.org/10.1158/1055‑9965.EPI‑20‑1389; Mohamad NV, Wong SK, Wan Hasan WN, Jolly JJ, Nur‑Farhana MF, Ima‑Nirwana S, et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male. 2019 Jun;22(2):129–140. https://doi.org/10.1080/13685538.2018.1482487; Baldassarri M, Picchiotti N, Fava F, Fallerini C, Benetti E, Daga S, et al. Shorter androgen receptor polyQ alleles protect against life‑threatening COVID‑19 disease in European males. EBioMedicine. 2021 Mar;65:103246. https://doi.org/10.1016/j.ebiom.2021.103246; Демидова Т. Ю., Волкова Е. И., Грицкевич Е. Ю. Особенности течения и последствия COVID‑19 у пациентов с избыточным весом и ожирением. Уроки текущей пандемии. Ожирение и метаболизм. 2020;17(4):375–384. https://doi.org/10.14341/omet12663; Lapauw B, Kaufman JM. Management of Endocrine Disease: Rationale and current evidence for testosterone therapy in the management of obesity and its complications. Eur J Endocrinol. 2020 Dec;183(6):R167–R183. https://doi.org/10.1530/EJE‑20‑0394; Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase‑4 (DPP4) inhibition in COVID‑19. Acta Diabetol. 2020 Jul;57(7):779–783. https://doi.org/10.1007/s00592‑020‑01539‑z; Tanezha V. Sex Hormones Determine Immune Response. Front Immunol. 2018;9:1931. https://doi.org/10.3389/fimmu.2018.01931; Reyes‑García J, Montaño LM, Carbajal‑García A, Wang YX. Sex Hormones and Lung Inflammation. Adv Exp Med Biol. 2021;1304:259–321. https://doi.org/10.1007/978‑3‑030‑68748‑9_15; Chanana N, Palmo T, Sharma K, Kumar R, Graham BB, Pasha Q. Sex‑derived attributes contributing to SARS‑CoV‑2 mortality. Am J Physiol Endocrinol Metab. 2020 Sep 1;319(3):E562–E567. https://doi.org/10.1152/ajpendo.00295.2020; Messina G, Polito R, Monda V, Cipolloni L, Di Nunno N, Di Mizio G, et al. Functional Role of Dietary Intervention to Improve the Outcome of COVID‑19: A Hypothesis of Work. Int J Mol Sci. 2020 Apr 28;21(9):3104. https://doi.org/10.3390/ijms21093104; Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID‑19 pneumonia. Cytokine Growth Factor Rev. 2020 Jun;53:38–42. https://doi.org/10.1016/j.cytogfr.2020.04.002; Papadopoulos V, Li L, Samplaski M. Why does COVID‑19 kill more elderly men than women? Is there a role for testosterone? Andrology. 2021 Jan;9(1):65–72. https://doi.org/10.1111/andr.12868; Van den Berg DF, Te Velde AA. Severe COVID‑19: NLRP3 Inflammasome Dysregulated. Front Immunol. 2020 Jun 26;11:1580. https://doi.org/10.3389/fimmu.2020.01580; Chen S, Markman JL, Shimada K, Crother TR, Lane M, Abolhesn A, et al. Sex‑Specific Effects of the Nlrp3 Inflammasome on Atherogenesis in LDL Receptor‑Deficient Mice. JACC Basic Transl Sci. 2020 Jun;5(6):582–598. https://doi.org/10.1016/j.jacbts.2020.03.016; Flaifel A, Guzzetta M, Occidental M, Najari BB, Melamed J, Thomas KM, et al. Testicular Changes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2). Arch Pathol Lab Med. 2021 Jan 1;145(1):8–9. https://doi.org/10.5858/arpa.2020‑0487‑LE; Duarte‑Neto AN, Teixeira TA, Caldini EG, Kanamura CT, Gomes‑Gouvêa MS, Dos Santos ABG, et al. Testicular pathology in fatal COVID‑19: A descriptive autopsy study. Andrology. 2022 Jan;10(1):13–23. https://doi.org/10.1111/andr.13073; Shi T, Dansen TB. Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both? Antioxid Redox Signal. 2020 Oct 20;33(12):839–859. https://doi.org/10.1089/ars.2020.8074; Grimes JM, Grimes KV. p38 MAPK inhibition: A promising therapeutic approach for COVID‑19. J Mol Cell Cardiol. 2020 Jul;144:63–65. https://doi.org/10.1016/j.yjmcc.2020.05.007; Jing J, Ding N, Wang D, Ge X, Ma J, Ma R, et al. Oxidized‑LDL inhibits testosterone biosynthesis by affecting mitochondrial function and the p38 MAPK/COX‑2 signaling pathway in Leydig cells. Cell Death Dis. 2020 Aug 14;11(8):626. https://doi.org/10.1038/s41419‑020‑02751‑z; Dhindsa S, Zhang N, McPhaul MJ, Wu Z, Ghoshal AK, Erlich EC, et al. Association of Circulating Sex Hormones With Inflammation and Disease Severity in Patients With COVID‑19. JAMA Netw Open. 2021 May 3;4(5):e2111398. https://doi.org/10.1001/jamanetworkopen.2021.11398; Schroeder M, Schaumburg B, Mueller Z, Parplys A, Jarczak D, Roedl K, et al. High estradiol and low testosterone levels are associated with critical illness in male but not in female COVID‑19 patients: a retrospective cohort study. Emerg Microbes Infect. 2021 Dec;10(1):1807–1818. https://doi.org/10.1080/22221751.2021.1969869; Kyrou I, Karteris E, Robbins T, Chatha K, Drenos F, Randeva HS. Polycystic ovary syndrome (PCOS) and COVID‑19: an overlooked female patient population at potentially higher risk during the COVID‑19 pandemic. BMC Med. 2020 Jul 15;18(1):220. https://doi.org/10.1186/s12916‑020‑01697‑5; Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, et al. Low testosterone levels predict clinical adverse outcomes in SARS‑CoV‑2 pneumonia patients. Andrology. 2021 Jan;9(1):88–98. https://doi.org/10.1111/andr.12821; Cinislioglu AE, Cinislioglu N, Demirdogen SO, Sam E, Akkas F, Altay MS, et al. The relationship of serum testosterone levels with the clinical course and prognosis of COVID‑19 disease in male patients: A prospective study. Andrology. 2022 Jan;10(1):24–33. https://doi.org/10.1111/andr.13081; Ma L, Xie W, Li D, Shi L, Mao Y, Xiong Y, et al. Effect of SARS‑CoV‑2 infection upon male gonadal function: A single center‑based study. medRxiv. 2020 Jan 1;2020.03.21.20037267. https://doi.org/10.1101/2020.03.21.20037267; Datta S, Sengupta P. SARS‑CoV‑2 and Male Infertility: Possible Multifaceted Pathology. Reprod Sci. 2021 Jan;28(1):23–26. https://doi.org/10.1007/s43032‑020‑00261‑z; Rambhatla A, Bronkema CJ, Corsi N, Keeley J, Sood A, Affas Z, et al. COVID‑19 Infection in Men on Testosterone Replacement Therapy. J Sex Med. 2021 Jan;18(1):215–218. https://doi.org/10.1016/j.jsxm.2020.09.013; Bianchi VE. The Anti‑Inflammatory Effects of Testosterone. J Endocr Soc. 2019 Jan 1;3(1):91–107. https://doi.org/10.1210/js.2018‑00186; Aboudounya MM, Heads RJ. COVID‑19 and Toll‑Like Receptor 4 (TLR4): SARS‑CoV‑2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation. Mediators Inflamm. 2021;2021:8874339. https://doi.org/10.1155/2021/8874339; Pozzilli P, Lenzi A. Commentary: Testosterone, a key hormone in the context of COVID‑19 pandemic. Metabolism. 2020 Jul;108:154252. https://doi.org/10.1016/j.metabol.2020.154252; Salonia A, Corona G, Giwercman A, Maggi M, Minhas S, Nappi RE, et al. SARS‑CoV‑2, testosterone and frailty in males (PROTEGGIMI): A multidimensional research project. Andrology. 2021 Jan;9(1):19–22. https://doi.org/10.1111/andr.12811; Koskinen M, Carpen O, Honkanen V, Seppänen MRJ, Miettinen PJ, Tuominen JA, et al. Androgen deprivation and SARS‑CoV‑2 in men with prostate cancer. Ann Oncol. 2020 Oct;31(10):1417–1418. https://doi.org/10.1016/j.annonc.2020.06.015; https://www.rpmj.ru/rpmj/article/view/813
-
4Academic Journal
Συγγραφείς: B. Ya. Alekseev, K. M. Nyushko, R. A. Gafanov, A. A. Kirichek, Yu. V. Anzhiganova, E. I. Kopyltsov, Yu. Yu. Sundui, Е. D. Pashanov, A. N. Petyushin, V. B. Matveev, Б. Я. Алексеев, К. М. Нюшко, Р. А. Гафанов, А. А. Киричек, Ю. В. Анжиганова, Е. И. Копыльцов, Ю. Ю. Сундуй, Е. Д. Пашанов, А. Н. Петюшин, В. Б. Матвеев
Συνεισφορές: The study was performed with the support of Janssen, pharmaceutical companies of Johnson & Johnson, Medical Department, Moscow, Russia, Исследование проведено при поддержке компании Янссен, подразделение фармацевтических товаров ООО «Джонсон & Джонсон», Москва, Россия
Πηγή: Cancer Urology; Том 18, № 2 (2022); 111-122 ; Онкоурология; Том 18, № 2 (2022); 111-122 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: андрогендепривационная терапия, prostate-specific antigen doubling time, new generation antiandrogen, androgen deprivation therapy, время удвоения простатического специфического антигена, антиандроген нового поколения
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1609/1372; Rawla P. Epidemiology of prostate cancer. World J Oncol 2019;10(2):63–89. DOI:10.14740/wjon1191; Simone G. The Epidemiology of prostate cancer. In: Prostate Cancer. Eds.: S.R.J. Bott, K.L. Ng. Australia, Brisbane: Exon Publications. DOI:10.36255/exonpublications.prostatecancer.epidemiology.2021; Mottet N., Cornford P., van den Bergh R.C.N. et al. EAUESTRO‑SIOG Guidelines on Prostate Cancer. Eur Urol 2018. Available at: https://uroweb.org/guideline/prostatecancer.; Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI:10.3322/caac.21492; Thurin N.H., Rouyer M., Gross‑Goupil M. et al. Epidemiology of metastatic castration‑resistant prostate cancer: a first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiol 2020;69:101833. DOI:10.1016/j.canep.2020.101833; Wallace K.L., Landsteiner A., Bunner S.H. et al. Increasing prevalence of metastatic castration‑resistant prostate cancer in a managed care population in the United States. Cancer Causes Control 2021;32(12):1365–74. DOI:10.1007/s10552‑021‑01484‑4; Ferlay J.E.M., Lam F., Colombet M. et al. Global cancer observatory: cancer tomorrow. Lyon, France: International Agency for Research on Cancer. Available at: https://gco.iarc.fr/tomorrow.; Состояние онкологической помощи населению России в 2020 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 239 с.; Рева С.А., Носов А.К., Король В.Д. и др. Сравнение результатов лечения больных раком предстательной железы высокого риска по критериям EAU и NCCN. Онкоурология 2021;17(2):54–61. DOI:10.17650/1726‑9776‑2021‑172‑54‑61; Сомов А.Н., Суслин С.А. Рак предстательной железы. Эпидемиология, факторы риска и раннее выявление. Профилактическая медицина 2020; 23(3):149–55. DOI:10.17116/profmed202023031149; Ahdoot M., Wilbur A.R., Reese S.E. et al. MRI‑targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med 2020;382(10):917–28. DOI:10.1056/NEJMoa1910038; Алексеев Б.Я., Крашенинников А.А., Нюшко К.М. и др. Хирургическое лечение больных раком предстательной железы с высоким риском прогрессирования: отдаленные онкологические результаты и факторы прогноза. Онкоурология 2020;16(4):99–111. DOI:10.17650/1726‑9776‑2020‑16‑4‑99‑111; American Cancer Society. Cancer Facts & Figures. Available at: https://www.cancer.org/content/dam/cancer‑org/research/cancer‑facts‑and‑statistics/annual‑cancerfacts‑and‑figures/2020/cancerfactsand‑figures‑2020.pdf.; Kirby M., Hirst C., Crawford E.D. Characterising the castration‑resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180–92. DOI:10.1111/j.1742‑1241.2011.02799.x; Leeman J.E., Chen M.H., Huland H. et al. Advancing age and the odds of upgrading and upstaging at radical prostatectomy in men with Gleason score 6 prostate cancer. Clin Genitourin Cancer 2019;17(6):e1116–21. DOI:10.1016/j.clgc.2019.07.018; Alchin D.R., Murphy D., Lawrentschuk N. Risk factors for Gleason score upgrading following radical prostatectomy. Minerva Urol Nefrol 2017;69(5):459–65. DOI:10.23736/S0393‑2249.16.02684‑9; Жаринов Г.М., Богомолов О.А. Исходное время удвоения простатспецифического антигена: клиническое и прогностическое значение у больных раком предстательной железы. Онкоурология 2014;10(1):44–8. DOI:10.17650/1726‑97762014‑10‑1‑44‑48; Milecki P., Antczak A., Martenka P., Kwias Z. What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision‑making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer? Cent European J Urol 2011;64(2):67–70. DOI:10.5173/ceju.2011.02.art3; Howard L.E., Moreira D.M., De Hoedt A. et al. Thresholds for PSA doubling time in men with non‑metastatic castration‑resistant prostate cancer. BJU Int 2017;120(5B):E80–6. DOI:10.1111/bju.13856; Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‑resistant nonmetastatic prostate cancer. Cancer 2011;117(10):2077–85. DOI:10.1002/cncr.25762; Liede A., Arellano J., Hechmati G. et al. International prevalence of nonmetastatic (M0) castration‑resistant prostate cancer (CRPC). J Clin Oncol 2013;31(15_suppl): e16052. DOI:10.1200/jco.2013.31.15_suppl.e16052; Parker C., Castro E., Fizazi K. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol 2020;31(9):1119–34. DOI:10.1016/j.annonc.2020.06.011; Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53(1):68–80. DOI:10.1016/j.eururo.2007.09.002; Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020;10:33.; Клинические рекомендации. Рак предстательной железы. Министерство здравоохранения Российской Федерации, 2020. 142 с.; Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis‑free survival in prostate cancer. N Engl J Med 2018;378(15):1408–18. DOI:10.1056/NEJMoa1715546; Smith M.R., Saad F., Chowdhury S. Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79(1):150–8. DOI:10.1016/j.eururo.2020.08.011; Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration‑resistant prostate cancer. N Engl J Med 2018;378(26):2465–74. DOI:10.1056/NEJMoa1800536; Sternberg C.N., Fizazi K., Saad F. Enzalutamide and survival in nonmetastatic, castration‑resistant prostate cancer. N Engl J Med 2020;382(23):2197–206. DOI:10.1056/NEJMoa2003892; https://oncourology.abvpress.ru/oncur/article/view/1609
-
5Academic Journal
Συγγραφείς: K. M. Nyushko, B. Ya. Alekseev, V. M. Perepukhov, I. M. Shevchuk, V. A. Atduev, А. B. Zdobnikov, V. B. Venskel, Е. V. Gurin, A. V. Eremenko, I. V. Belov, V. D. Gavrilova, R. M. Ismakov, D. G. Prokhorov, R. V. Nikitin, E. A. Usinin, E. I. Kopyltsov, O. V. Leonov, А. O. Leonov, К. М. Нюшко, Б. Я. Алексеев, В. М. Перепухов, И. М. Шевчук, В. А. Атдуев, А. Б. Здобников, В. Б. Венскель, Э. В. Гурин, А. В. Еременко, И. В. Белов, В. Д. Гаврилова, Р. М. Исмаков, Д. Г. Прохоров, Р. В. Никитин, Е. А. Усынин, Е. И. Копыльцов, О. В. Леонов, А. О. Леонова
Συνεισφορές: The study was performed without external funding, Исследование проведено без спонсорской поддержки
Πηγή: Cancer Urology; Том 18, № 2 (2022); 102-110 ; Онкоурология; Том 18, № 2 (2022); 102-110 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: антагонист лютеинизирующего гонадотропин-рилизинг-гормона, androgen-deprivation therapy, castration level of testosterone, degarelix, luteinizing hormonereleasing hormone antagonist, андрогендепривационная терапия, кастрационный уровень тестостерона, дегареликс
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1608/1371; Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.; Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;19:293–7.; Crawford E.D. Hormonal therapy in prostate cancer: historical approaches. Rev Urol 2004;6(Suppl 7): S3–11.; Грицкевич А.А., Медведев В.Л., Теплов А.А. и др. Современные возможности антагонистов лютеинизирующего гормона-рилизинг-гормона третьего поколения в лечении гормоночувствительного рака предстательной железы. Онкология. Журнал им. П.А. Герцена 2014;3(6):63–71.; Persson B.E., Olesen T.K., Jensen J.K. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90(3):235–44. DOI:10.1159/000228832; Mongiat-Artus P., Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(10):2171–9. DOI:10.1517/14656566.5.10.2171; Frampton J.E., Lyseng-Williamson K.A. Degarelix. Drugs 2009;69(14):1967–76. DOI:10.2165/10484080-00000000000000; Steinberg M. Degarelix: a gonadotropin releasing hormone antagonist for the management of prostate cancer. Clin Ther 2009;31:2312–31. DOI:10.1016/j.clinthera.2009.11.009; White R., Schwach G., Schteingart C. Degarelix, a unique, sustained-release depot GnRH blocker with a long duration of action. 1st European Multidisciplinary Meeting on Urological Cancers. Barcelona, 24 November 2007. Abstract P92. Available at: http://www.emucbarcelona2007.org/fileadmin/user_upload/downloads/EMUC_Binnen.pdf (accessed 31 July 2012).; Gittelman M., Pommerville P.J., Persson B.E. et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008;180(5):1986–92. DOI:10.1016/j.juro.2008.07.033; Van Poppel H., Tombal B., de la Rosette J.J. et al. Degarelix: a novel gonadotropinreleasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54(4):805–13. DOI:10.1016/j.eururo.2008.04.065; Ozono S., Ueda T., Hoshi S. et al. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol 2012;42(6):477–84. DOI:10.1093/jjco/hys035; Klotz L., Boccon-Gibod L., Shore N. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 2008;102(11):1531–8. DOI:10.1111/j.1464-410X.2008.08183.x; Hosseini S.A., Rajabi F., Akbari Sari A. et al. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. Med J Islam Repub Iran 2016;30:317.; Sun Y., Xie L., Xu T. et al. Efficacy and safety of degarelix in patients with prostate cancer: results from a phase III study in China. Asian J Urol 2020;7(3):301–8. DOI:10.1016/j.ajur.2019.09.003; Sciarra A., Fasulo A., Ciardi A. et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine 2016;95(27):e3845. DOI:10.1097/MD.0000000000003845; Smith M., Klotz L., Persson B.E. et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel-group phase III trial in patients with prostate cancer. J Urol 2010;184(6):2313–9. DOI:10.1016/j.juro.2010.08.012; European association of urology (EAU) Guidelines on prostate cancer. 2016. MT/W/0001/pdWS/001.; Geiges G., Harms T., Rodemer G. et al. Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry. BMC Urol 2015;15122. DOI:10.1186/s12894-015-0116-4; https://oncourology.abvpress.ru/oncur/article/view/1608
-
6Academic Journal
Συγγραφείς: S. Chowdhury, S. Oudard, H. Uemura, S. Joniau, L. Dearden, C. Capone, S. van Sanden, J. Diels, B. A. Hadaschik
Πηγή: Onkourologiâ, Vol 18, Iss 1, Pp 77-89 (2022)
Θεματικοί όροι: андрогендепривационная терапия, апалутамид, даролутамид, неметастатический кастрационнорезистентный рак предстательной железы, онкология, Medicine
Relation: https://oncourology.abvpress.ru/oncur/article/view/1577; https://doaj.org/toc/1726-9776; https://doaj.org/toc/1996-1812; https://doaj.org/article/0c66917ab98c4548bfa2f76181e5d8bc
-
7Academic Journal
Συγγραφείς: Spirina L.V., Gorbunov A.K., Kondakova I.V., Usynin E.A., Slonimskaya E.M.
Συνεισφορές: Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, НИИ онкологии ФГБНУ «Томский национальный исследовательский медицинский центр РАН»
Πηγή: Advances in Molecular Oncology; Vol 6, No 1 (2019); 44-48 ; Успехи молекулярной онкологии; Vol 6, No 1 (2019); 44-48 ; 2413-3787 ; 2313-805X
Θεματικοί όροι: prostate cancer, AR, ER, testosterone, prostate specific antigen, androgen-deprivation therapy, рак предстательной железы, тестостерон, простатический специфический антиген, андрогендепривационная терапия
Περιγραφή αρχείου: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/205/173; https://umo.abvpress.ru/jour/article/view/205
-
8Academic Journal
Συγγραφείς: R. A. Gafanov, A. G. Dzidzaria, I. B. Kravtsov, S. V. Fastovets, Р. А. Гафанов, А. Г. Дзидзария, И. Б. Кравцов, С. В. Фастовец
Πηγή: Cancer Urology; Том 14, № 4 (2018); 139-149 ; Онкоурология; Том 14, № 4 (2018); 139-149 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-4
Θεματικοί όροι: энзалутамид, androgen-deprivation therapy, docetaxel, abiraterone, enzalutamide, андрогендепривационная терапия, доцетаксел, абиратерон
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/910/817; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. DOI:10.3322/caac.21442. PMID: 29313949.; Jemal A., Fedewa S.A., Ma J. et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314(19):2054—61. DOI:10.1001/jama.2015.14905. PMID: 26575061.; Weiner A.B., Matulewicz R.S., Eggener S.E., Schaeffer E.M. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 2016;19(4):395—7. DOI:10.1038/pcan.2016.30. PMID: 27431496.; Dalela D., Sun M., Diaz M. et al. Contemporary trends in the incidence of metastatic prostate cancer among US men: results from nationwide analyses. Eur Urol Focus 2017. DOI:10.1016/j.euf.2017.04.012. PMID: 28753893.; National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts. Prostate Cancer. Available at: https://seer.cancer.gov/statfacts/html/prost.html. Accessed January 7, 2018.; Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;167(2 Pt 2):948-51, discussion 952. PMID: 11905923.; Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8): 737-46. DOI:10.1056/NEJMoa1503747.; James N.D., Sydes M.R., Clarke N.W. et al. STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163—77. DOI:10.1016/S0140-6736(15)01037-5. PMID: 26719232.; Гафанов Р.А. Гормональная и химиотерапия у больных гормончувствительным раком предстательной железы. Онкоурология 2016;12(1):63—8. DOI:10.17650/1726-9776-2016-12-1-63-68.; Fizazi K., Tran N., Fein L. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352—60. DOI:10.1056/NEJMoa1704174. PMID: 28578607.; James N.D., de Bono J.S., Spears M.R. et al. STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377:338-51.; Massie C.E., Lynch A., Ramos-Montoya A. et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011;30(13):2719—33. DOI:10.1038/emboj.2011.158. PMID: 21602788.; Harris W.P., Mostaghel E.A, Nelson P.S. et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6(2):76-85. DOI:10.1038/ncpuro1296. PMID: 19198621.; Clinton T.N., Woldu S.L., Raj G.V. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. Expert Opin Pharmacother 2017;18(8):825—32. DOI:10.1080/14656566.2017.1328056. PMID: 28480768.; Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77. PMID: 10744594.; Hussain M., Tangen C.M., Berry D.L. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368(14):1314—25. DOI:10.1056/NEJMoa1212299. PMID: 23550669.; Hussain M., Tangen C.M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984-90. DOI:10.1200/JCO.2006.06.4246. PMID: 16921051.; Klotz L., O’Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151-6. DOI:10.1200/JCO.2014.58.2973. PMID: 25732157.; Hahn A.W., Hale P., Rathi N. et al. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Curr Opin Urol 2017;27(6): 559-65. DOI:10.1097/MOU.0000000000000443. PMID: 28816716.; McLeod D., Zinner N., Tomera K. et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58(5):756-61. PMID: 11711355.; Morote J., Esquena S., Abascal J.M. et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006;77(2):135-8. DOI:10.1159/000093907. PMID: 16888418.; Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 2007; 100 Suppl 1:6-11. DOI:10.1111/j.1464-410X.2007.6976.x. PMID: 17593202.; Schulman C., Alcaraz A., Berges R. et al. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int 2007;100 Suppl 1:1-5. DOI:10.1111/j.1464-410X.2007.06967.x. PMID: 17593201.; Perez-Marrero R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447-57. DOI:10.1517/14656566.5.2.447. PMID: 14996640.; Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61(2 Suppl 1):25— 31. PMID: 12667884.; Shore N.D., Chu F., Moul J. et al. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int 2017;119(2):239—44. DOI:10.1111/bju.13482. PMID: 26991743.; Sweeney C., Chen Y., Liu G. et al. Long term efficacy and QOL data of chemohormonal therapy in low and high volume hormone naive metastatic prostate cancer: E3805 CHAARTED trial. Ann Oncol 2016;27(suppl_6):243-65.; Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149—58. DOI:10.1016/S1470-2045(12)70560-0. PMID: 23306100.; Gravis G., Boher J.M., Joly F. et al. GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU 15 Trial. Eur Urol 2016;70:256-62.; Sridhar S.S., Sweeney C.J. It is time to harmonize the design and conduct of clinical trials in metastatic hormone-sensitive prostate cancer. Eur Urol 2016;70(2):263—4. DOI:10.1016/j.eururo.2015.11.025. PMID: 26683759.; Vale C.L., Burdett S., Rydzewska L.H.M. et al. STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and metaanalyses of aggregate data. Lancet Oncol 2016;17:243-56.; de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995—2005. DOI:10.1056/NEJMoa1014618. PMID: 21612468.; Павлов А.Ю., Гафанов Р.А., Цыбульский А.Д. и др. Современная стратегия лекарственной терапии метастатического и гормон-резистентного рака предстательной железы. Российский медицинский журнал 2016;(8):476—9.; Ryan C.J., Smith M.R., de Bono J.S. et al. COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138—48. DOI:10.1056/NEJMoa1209096. PMID: 23228172.; Hoyle A. Role ofAAP + ADT in low- and high-risk mHNPC. ESMO 2018. Oral LBA4.; Scher H.I., Fizazi K., Saad F. et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187—97. DOI:10.1056/45.NEJMoa1207506. PMID: 22894553.; Beer T.M., Armstrong A.J., Rathkopf D.E. et al. PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(18):424—33. DOI:10.1056/NEJMc1410239. PMID: 25354111.46.; Алексеев Б.Я., Матвеев В.Б., Русаков И.Г. и др. Резолюция по итогам Совещания экспертов по лечению гормон-резистентного рака предстательной железы. Онкоурология 2016;12(3):109—10.; Hussain M., Karim Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465—74. DOI:10.1056/NEJMoa1800536. PMID: 29949494.; Small E.J., Saad F., Chowdhury S. et al. SPARTAN, a phase 3 doubleblind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 2018;36(6 suppl; abstr 161).; Rathkopf D.E., Antonarakis E.S., Shore N.D. et al. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin Cancer Res 2017;23(14):3544—51. DOI:10.1158/1078-0432.CCR-16-2509. PMID: 28213364.; Shore N.D. Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother 2017;18(9):945—52. DOI:10.1080/14656566.2017.1329820. PMID: 28490267.; Fizazi K., Massard C., Bono P. et al. ARADES study group. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 2014;15(9):975—85. DOI:10.1016/S1470-2045(14)70240-2. PMID: 24974051.; Lenis A.T., Salmasi A.H., Donin N.M. et al. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urol Oncol 2018;36(2): 78.e21—8. DOI:10.1016/j.urolonc.2017.09.030. PMID: 29128421.; Culp S.H., Schellhammer P.F., Williams M.B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65(6):1058—66. DOI:10.1016/j.eururo.2013.11.012. PMID: 24290503.; Tosoian J.J., Gorin M.A., Ross A.E. et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017;14(1):15—25. DOI:10.1038/nrurol.2016.175. PMID: 27725639.; Rusthoven C.G., Jones B.L., Flaig T.W. et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 2016;34(24):2835—42. DOI:10.1200/JCO.2016.67.4788. PMID: 27325855.; Satkunasivam R., Kim A.E., Desai M. et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol 2015;194:378—85.; Gratzke C., Engel J., Stief C.G. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 2014;66(3):602—3. DOI:10.1016/j.eururo.2014.04.009. PMID: 24821581.; Cho Y., Chang J.S., Rha K.H. et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis? PLoS One 2016;11(1):e0147191. DOI:10.1371/journal.pone.0147191. PMID: 26807740.; Parker et al. Radiotherapy to the primary tumour for men with newly-diagnosed mPCa: survival results from STAMPEDE. ESMO 2018. Oral LBA5.; https://oncourology.abvpress.ru/oncur/article/view/910
-
9Academic Journal
Συγγραφείς: A. S. Markova, V. B. Matveev, А. С. Маркова, В. Б. Матвеев
Πηγή: Cancer Urology; Том 10, № 1 (2014); 76-81 ; Онкоурология; Том 10, № 1 (2014); 76-81 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2014-10-1
Θεματικοί όροι: дегареликс, androgen deprivation therapy, luteinizing hormone releasing hormone antagonists, degarelix, андрогендепривационная терапия, антагонисты лютеинизирующего гормона рилизинг-гормона
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/25/40; Heidenreich A., Bastian P. J., Bellmunt J. et al. EAU Guidelines 2013; p. 1–154.; Payne H., Mason M. Androgen deprivation therapy as adjuvant / neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011;105:1628–34.; Sharifi N., Gulley J. L., Dahut W. L. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17: 305–15.; Gittelman M., Pommerville P. J., Persson B. E. et al. A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 2008;180:1986–92.; Klotz L., Boccon-Gibod L., Shore N. D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531–8.; Van Poppel H., Tombal B., de la Rosette J. L. еt al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805–13.; Koechling W., Hjortkjaer R., Tankу L. B. Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol 2010;70:580–7.; Bhasin S., Berman N., Swerdloff R. S. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment. J Androl 1994;15:386–91.; Varenhorst E., Wallentin L., Carlstrцm K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol 1982;16:31–6.; Ben-Josef E., Yang S. Y., Ji T. H. et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161:970–6.; Mariani S., Salvatori L., Basciani S. et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006;175:2072–7.; Radu A., Pichon C., Camparo P. et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010;363:1621–30.; Canon J. G., Kraj B., Sloan G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokin 2011;53:141–4.; Tombal B., Berges R. Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl 2008;7:15–21.; Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 2005;4:14–9.; Perachino M., Cavalli V., Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105:648–51.; Miller K., Crawford D., Shore N. et al. Disease control-related outcomes from an analysis of six comparative randomized сlinical trials of degarelix versus luteinising hormone-releasing hormone (LHRH) agonists. 28 th EAU Congress. Milan, Italy. Poster 678.; Tombal B., Miller K., Boccon-Gibod L. et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010;57:836–2.; Tombal B., Albertsen P., de la Taille A. et al. Lower risk of cardiovascular (CV) events and death in men receiving ADTby gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists. 28 th EAU Congress. Milan, Italy. Poster 677.; Albertsen P. C., Klotz L., Tombal B. et al. Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. Eur Urol 2014;65:565–73.; Axcrona K., Aaltomaa S., da Silva C. M. et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int 2012;110 (11):1721–8.; Mason M., Maldonado Pijoan X., Steidle C. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus gosere-lin plus bicalutamide. Clin Oncol (R Coll Ra-diol) 2013;25 (3):190–6.; Albertsen P. C., Moore D. F., Shih W. et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29 (10):1335–41.; Conteduca V., DiLorenzo G., Tartaron A., Aita M. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer. An unresolved controversy. Crit Rev Oncol Hematol 2013;86:42–51.; Shahani S., Braga-Basaria M., Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93:2042–9.; Smith M. R., Finkelstein J. S., McGovern F. J. et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87 (2):599–603.; Smith M. R., Lee H., Nathan D. M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305–8.; Stanworth R. D., Jones T. H. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009;37:74–90.; D’Amico A. V., Denham J. W., Crook J. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420–5.; Keating N. L., O’Malley A. J., Freedland S. J., Smith M. R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39–43.; Keating N. L., O’Malley A. J., Smith M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24: 4448–56.; Levine G. N., D’Amico A. V., Berger P. et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010;121:833–40.; Saigal C. S., Gore J. L., Krupski T. L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493–500.; Tsai H. K., D’Amico A. V., Sadetsky N. et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Institute 2007;99:1516–24.; Alibhai S. M., Duong-Hua M., Sutradhar R. et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 7:3452–58.; Roach M., Bae K., Speight J. et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585–91.; Studer U. E., Whelan P., Albrecht W. et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24:1868–76.; Chen H. F., Jeung E. B., Stephenson M., Leung P. C. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84 (2):743–50.; Andersson J., Libby P., Hansson G. K. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134 (1):33–46.; https://oncourology.abvpress.ru/oncur/article/view/25
-
10Academic Journal
Πηγή: Онкоурология.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ,АНДРОГЕНДЕПРИВАЦИОННАЯ ТЕРАПИЯ,АНТАГОНИСТЫ ЛЮТЕИНИЗИРУЮЩЕГО ГОРМОНА РИЛИЗИНГ-ГОРМОНА,ДЕГАРЕЛИКС, 3. Good health
Περιγραφή αρχείου: text/html
-
11Academic Journal
Συγγραφείς: Тер-Ованесов М.Д., Ягудаев Д.М., Аниканова Е.В., Медведев К.И.
Πηγή: Onkourologiya
Θεματικοί όροι: prostate cancer, Oligometastasis, Metastasis-directed therapy, Androgen-deprivation therapy, рак предстательной железы, олигометастаз, метастазнаправленная терапия, андрогендепривационная терапия
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/111968/
-
12Academic Journal
Συγγραφείς: Popov S.V.
Πηγή: Медицинский совет
Θεματικοί όροι: рак предстательной железы, гормоночувствительность, олигометастазы, андрогендепривационная терапия, химиотерапия, доцетаксел, эффективность, prostate cancer, hormone sensitivity, oligometastases, androgen-deprivational therapy, chemotherapy, docetaxel, effectiveness
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/61105/
